To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Clinical trial NCT04796922 · WITHDRAWN
Trial details
- NCT number
- NCT04796922
- Sponsor
- Incyte Corporation
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-30
- Primary completion
- 2028-12-20
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.